Evidence map›Paper›PMID 33970941›Full record

ArticlePloS one2021

Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo.

Ryan S MacLeod, Mark B Meyer, Jinhu Xiong, Keisha M Cawley, Yu Liu, Melda Onal, Nancy A Benkusky, Jeff D Thostenson, J Wesley Pike, Charles A O'Brien

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ryan S MacLeodCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.ORCID 0000-0001-7797-2754
Mark B MeyerDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, United States of America.
Jinhu XiongCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Keisha M CawleyCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Yu LiuCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Melda OnalCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Nancy A BenkuskyDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, United States of America.
Jeff D ThostensonCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
J Wesley PikeDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, United States of America.
Charles A O'BrienCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.ORCID 0000-0002-5286-6821
University of Arkansas for Medical Sciences · USUniversity of Wisconsin–Madison · USCentral Arkansas Veterans Healthcare System · US

Funding

Understanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Amy Yoshiko Sato · 2018 to 2026
$23.0M
Research Supplement to Promote Diversity in Health-related ResearchR01AR049794 · NIAMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2003 to 2026
$6.3M
RANKL and lymphocyte-mediated bone lossI01BX000294 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI O'BRIEN, CHARLES A · 2009 to 2022
–
BLRD VA I01 BX000294NIAMS NIH HHS R01 AR049794NIGMS NIH HHS P20 GM125503
6 · The paper itself

Abstract

The cytokine RANKL is essential for osteoclast formation during physiological and pathological bone resorption. RANKL also contributes to lymphocyte production, development of lymph nodes and mammary glands, as well as other biological activities. Transcriptional control of the Tnfsf11 gene, which encodes RANKL, is complex and involves distant regulatory regions. Nevertheless, cell culture studies suggest that an enhancer region near the transcription start site is involved in the control of Tnfsf11 expression by hormones such as 1,25-(OH)2 vitamin D3 and parathyroid hormone, as well as the sympathetic nervous system. To address the significance of this region in vivo, we deleted the sequence between -510 to -1413 bp, relative to Tnfsf11 exon 1, from mice using CRISPR-based gene editing. MicroCT analysis of the femur and fourth lumbar vertebra of enhancer knockout mice showed no differences in bone mass compared to wild type littermates at 5 weeks and 6 months of age, suggesting no changes in osteoclast formation. RNA extracted from the tibia, fifth lumbar vertebra, thymus, and spleen at 6 months of age also showed no reduction in Tnfsf11 mRNA abundance between these groups. However, maximal stimulation of Tnfsf11 mRNA abundance in cultured stromal cells by PTH was reduced approximately 40% by enhancer deletion, while stimulation by 1,25-(OH)2 vitamin D3 was unaffected. The abundance of B and T lymphocytes in the bone marrow did not differ between genotypes. These results demonstrate that the region between -510 and -1413 does not contribute to Tnfsf11 expression, osteoclast support, or lymphocyte production in mice under normal physiological conditions but may be involved in situations of elevated parathyroid hormone.

Indexed as

AnimalsBone DensityCells, CulturedCRISPR-Cas SystemsFemaleLymphocytesMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutModels, AnimalOsteoclastsParathyroid HormonePromoter Regions, GeneticRANK LigandParathyroid HormoneRANK LigandTnfsf11 protein, mouse

Identifiers

PMID33970941
PMCPMC8109787
OpenAlexW3161937029

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.